Several metalloproteinases, but also the tissue inhibitors of metalloproteinases 1 and 2 (TIMP1 and TIMP2), which participate in the remodeling process of the extracellular matrix and have been shown to be upregulated in muscles and plasma from patients with DMD [60], were also decreased after nintedanib treatment. The gene discussed is TIMP1; the disease is Duchenne muscular dystrophy.